Segment Information

3 Months Ended

Mar. 31, 2020

We operate under two reportable segments: Healthcare and Research. The Healthcare segment is focused on remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders and to monitor the functionality of implantable cardiac devices. We offer cardiologists, electrophysiologists, neurologists and primary care physicians a full spectrum of solutions, which provides them with a single source of remote cardiac monitoring services. These services include MCT, event, traditional Holter, extended Holter, Pacemaker, International Normalized Ratio and Implantable Loop Recorder and other implantable cardiac device monitoring. The Research segment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. Included in the Corporate and Other category is the manufacturing, testing and marketing of cardiac and blood glucose monitoring devices to medical companies, clinics and hospitals and corporate overhead and other items not allocated to any of our reportable segments.

Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income/(loss). Any remaining expenses including integration and other charges, as well as the elimination of costs associated with intercompany revenue, are included in Corporate and Other. Also included in Corporate and Other is our net interest expense and other financing expenses. We do not allocate assets to the individual segments.



	Three Months Ended March 31, 2020
	Reporting Segment				Corporate and Other
(in thousands)	Healthcare		Research		Corporate and Other			Consolidated
Revenue	$	95,707	$	13,820	$	3,504		$	113,031
Gross profit	64,424		5,675		409			70,508
Income/(loss) before income taxes	29,876		2,043		(19,586		)	12,333
Depreciation and amortization	8,435		1,066		984			10,485
Capital expenditures	6,211		391		382			6,984



	Three Months Ended March 31, 2019
	Reporting Segment				Corporate and Other
(in thousands)	Healthcare		Research		Corporate and Other			Consolidated
Revenue	$	88,009	$	12,964	$	3,006		$	103,979
Gross profit	59,864		4,334		580			64,778
Income/(loss) before income taxes	29,608		764		(20,760		)	9,612
Depreciation and amortization	8,291		928		802			10,021
Capital expenditures	4,442		482		410			5,334